Understand the source comparison
Peptides for CIRS: Mechanism Comparison
Mast Cell Stabilisers (e.g., KPV) Inhibits NF-κB translocation, prevents degranulation MRGPRX2 receptor modulation, calcium channel regulation Reduces spontaneous histamine release, brain fog, flushing Preclinical models, in vitro data Strong mechanistic fit f
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Mast Cell Stabilisers (e.g., KPV)
- Inhibits NF-κB translocation, prevents degranulation
- MRGPRX2 receptor modulation, calcium channel regulation
- Reduces spontaneous histamine release, brain fog, flushing
- Preclinical models, in vitro data
- Strong mechanistic fit for histamine-dominant CIRS phenotypes; human trials needed
- Mitochondrial Repair (PGC-1α activators)
- Upregulates mitochondrial biogenesis via AMPK
- PGC-1α/SIRT1 pathway
- Restores ATP synthesis impaired by mycotoxin exposure
- Animal models, human exercise physiology data
- Addresses core energy deficit; 4–6 week lag before clinical effect
- Thymic Peptides (e.g., Thymalin)
- Expands Treg populations, restores Th17:Treg balance
- Foxp3 upregulation
- Rebalances immune dysregulation without broad suppression
- Human autoimmune studies, preclinical CIRS models
- Best evidence for immune rebalancing; requires 8–12 weeks for cytokine shifts
- Neuroprotective Peptides (e.g., Cerebrolysin)
- Protects neurons from oxidative stress, supports BDNF
- Mitochondrial stabilisation, neurotrophic signalling
- Targets cognitive dysfunction (brain fog, memory impairment)
- Stroke and TBI research, no direct CIRS trials
- Mechanistically sound for neuroinflammatory component; extrapolated from other conditions